| Fate mapping of mammalian embryonic taste bud progenitors S Thirumangalathu, DE Harlow, AL Driskell, RF Krimm, LA Barlow Oxford University Press for The Company of Biologists Limited 136 (9), 1519-1528, 2009 | 102 | 2009 |
| Remyelination Therapy in Multiple Sclerosis DE Harlow, JM Honce, AA Miravalle Frontiers in Neurology 6, 257, 2015 | 97 | 2015 |
| Inhibitors of myelination: ECM changes, CSPGs and PTPs DE Harlow, WB Macklin Experimental neurology 251, 39-46, 2014 | 87 | 2014 |
| Myelin proteolipid protein complexes with αv integrin and AMPA receptors in vivo and regulates AMPA-dependent oligodendrocyte progenitor cell migration through the modulation … DE Harlow, KE Saul, H Komuro, WB Macklin Journal of Neuroscience 35 (34), 12018-12032, 2015 | 59 | 2015 |
| Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination Y Liu, KS Given, DE Harlow, AM Matschulat, WB Macklin, JL Bennett, ... Acta neuropathologica communications 5, 1-13, 2017 | 58 | 2017 |
| Expression of proteolipid protein gene in spinal cord stem cells and early oligodendrocyte progenitor cells is dispensable for normal cell migration and myelination DE Harlow, KE Saul, CM Culp, EM Vesely, WB Macklin Journal of Neuroscience 34 (4), 1333-1343, 2014 | 50 | 2014 |
| Embryonic origin of gustatory cranial sensory neurons DE Harlow, LA Barlow Developmental biology 310 (2), 317-328, 2007 | 40 | 2007 |
| Epibranchial placode‐derived neurons produce BDNF required for early sensory neuron development DE Harlow, H Yang, T Williams, LA Barlow Developmental Dynamics 240 (2), 309-323, 2011 | 21 | 2011 |
| The impact of fremanezumab on medication overuse in patients with chronic migraine (vol 19, pg P12, 2018) SD Silberstein, S Ashina, Z Katsarava, K Bibeau, MJ Seminerio, ... JOURNAL OF HEADACHE AND PAIN 19, 2018 | 16 | 2018 |
| The Protein Tyrosine Phosphatase Shp2 Regulates Oligodendrocyte Differentiation and Early Myelination and Contributes to Timely Remyelination JT Ahrendsen, DE Harlow, LT Finseth, JN Bourne, SP Hickey, EA Gould, ... Journal of Neuroscience 38 (4), 787-802, 2018 | 13 | 2018 |
| Variable sensitivity to complement-dependent cytotoxicity in murine models of neuromyelitis optica Y Liu, DE Harlow, KS Given, GP Owens, WB Macklin, JL Bennett Journal of Neuroinflammation 13, 1-16, 2016 | 13 | 2016 |
| The impact of fremanezumab on medication overuse in patients with chronic migraine (P1. 10-026) S Silberstein, S Ashina, Z Katsarava, K Bibeau, M Seminerio, D Harlow, ... Neurology 92 (15 Supplement), 2019 | 10 | 2019 |
| CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis AA Miravalle, J Katz, D Robertson, B Hayward, DE Harlow, LA Lebson, ... Neurodegenerative Disease Management 11 (2), 99-111, 2021 | 9 | 2021 |
| ND3 USE OF GROUP-BASED TRAJECTORY MODELING TO IDENTIFY ADHERENCE CLUSTERS IN PATIENTS WITH MULTIPLE SCLEROSIS NEWLY-INITIATING ONCE-OR TWICE-DAILY ORAL DISEASE-MODIFYING DRUGS J Nicholas, NC Edwards, RA Edwards, A Dellarole, L Manca, DE Harlow, ... Value in Health 22, S43, 2019 | 3 | 2019 |
| The effect of disease modifying therapies on fatigue in multiple sclerosis SC Rivera, OL Aiyegbusi, DP Meier, A Dunne, DE Harlow, C Henke, ... Multiple Sclerosis and Related Disorders, 105065, 2023 | 2 | 2023 |
| Static and group-based trajectory analyses of factors associated with non-adherence in patients with multiple sclerosis newly-initiating once-or twice-daily oral disease … JA Nicholas, NC Edwards, RA Edwards, A Dellarole, L Manca, DE Harlow, ... Multiple Sclerosis Journal–Experimental, Translational and Clinical 8 (2 …, 2022 | 2 | 2022 |
| Genome-wide mapping of patient autoantibody targets to understand and predict multiple sclerosis pathogenesis and patient responses to interferon beta-1a therapy EB DiCillo, E Kountikov, M Zhu, W Zhang, B Hayward, DE Harlow, ... 37th Congress of the European Committee for Treatment and Research in …, 2021 | 1 | 2021 |
| Cladribine tablets: observational evaluation of effectiveness, safety, and patient reported outcomes in suboptimally controlled patients previously taking injectable disease … A Miravalle, J Katz, B Hayward, J Walsh, D Harlow Presented at European Committee for Treatment and Research in Multiple …, 2019 | 1 | 2019 |
| PND91 PREDICTORS OF NON-ADHERENCE AMONG PATIENTS WITH MULTIPLE SCLEROSIS NEWLY INITIATING ONCE-OR TWICE-DAILY ORAL DISEASE-MODIFYING DRUGS J Nicholas, NC Edwards, RA Edwards, A Dellarole, L Manca, DE Harlow, ... Value in Health 22, S287, 2019 | 1 | 2019 |
| B Lymphocytes from MS Patients Induce CNS Pathology in a Murine Brain Slice Model (P5. 321) D Harlow, K Blauth, K Saul, S Selva, T Niedzielko, L Jackson, W Macklin, ... Neurology 86 (16_supplement), P5. 321, 2016 | 1 | 2016 |
Elisa VeselyPostdoctoral ResearcherDirección de correo verificada de dartmouth.edu
